The Committee for Medicinal Products for Human Use (CHMP) issued an opinion supporting Mayzent (siponimod) as an oral treatment specifically for adults with active secondary progressive multiple sclerosis (SPMS) in the European Union. Opinions released by CHMP, an arm of the European Medicines Agency (EMA), carry weight and are…
Alexa
Recommended Posts
- Naming abuse, intentional or not, in caregiver-patient relationships
- Melatonin supplements can boost the benefits of exercise for MS
- Common fever meds may ease MS fatigue, boost exercise capacity
- FDA OKs first human trial of oral MS remyelination therapy PTD802
- Taking high-dose vitamin D daily over the long term helps reduce MS relapses